Page 15 - TD-3-1

Tumor Discovery Haplotype and LD of BRCA genes in GBM

doi: 10.5306/wjco.v11.i2.53 30. Sim HW, McDonald KL, Lwin Z, et al. A randomized
phase II trial of veliparib, radiotherapy, and temozolomide
24. Terkelsen T, Christensen LL, Fenton D, et al. Population
frequencies of pathogenic alleles of BRCA1 and BRCA2: in patients with unmethylated MGMT glioblastoma: The
Analysis of 173 Danish breast cancer pedigrees using the VERTU study. Neuro Oncol. 2021;23:1736-1749.
BOADICEA model. Fam Cancer. 2019;18:381-388. doi: 10.1093/neuonc/noab111
doi: 10.1007/s10689-019-00141-9 31. Pishvaian MJ, Slack RS, Jiang W, et al. A phase 2 study of
the PARP inhibitor veliparib plus temozolomide in patients
25. Nageeb A, Mohamed M, Ezz El Arab LR, Khalifa MK,
Swellam M. Next generation sequencing of BRCA genes in with heavily pretreated metastatic colorectal cancer. Cancer.
glioblastoma multiform Egyptian patients: A pilot Study. 2018;124:2337-2346.
Arch Physiol Biochem. 2020;128:809-817. doi: 10.1002/cncr.31309
doi: 10.1080/13813455.2020.1729814 32. Xu J, Keenan TE, Overmoyer B, et al. Phase II trial of veliparib
and temozolomide in metastatic breast cancer patients with
26. Massarat AR, Lamkin M, Reeve C, Williams AL, D’Antonio M, and without BRCA1/2 mutations. Breast Cancer Res Treat.
Gymrek M. Haptools: A toolkit for admixture and haplotype 2021;189:641-651.
analysis. Bioinformatics. 2023;39(3):btad104.
doi: 10.1007/s10549-021-06292-7
doi: 10.1093/bioinformatics/btad104
33. Ding J, Wu S, Zhang C, et al. BRCA1 identified as a modulator
27. Freedman ML, Penney KL, Stram DO, et al. Common of temozolomide resistance in P53 wild-type GBM using a
variation in BRCA2 and breast cancer risk: A haplotype- high-throughput shRNA-based synthetic lethality screening.
based analysis in the multiethnic cohort. Hum Mol Genet. Am J Cancer Res. 2019;9(11):2428-2441.
2004;13:2431-2441.
34. De Asis Tuazon A, Lott P, Bohórquez M, et al. Haplotype
doi: 10.1093/hmg/ddh270
analysis of the internationally distributed BRCA1
28. Bhamidipati D, Haro-Silerio JI, Yap TA, Ngoi N. c.3331_3334delCAAG founder mutation reveals a common
PARP inhibitors: Enhancing efficacy through rational ancestral origin in Iberia. Breast Cancer Res. 2020;22:108.
combinations. Br J Cancer. 2023;129:904-916.
doi: 10.1186/s13058-020-01341-3
doi: 10.1038/s41416-023-02326-7
35. Vassilakopoulou M, Won M, Curran WJ, et al. BRCA1
29. Gill SJ, Travers J, Pshenichnaya I, et al. Combinations of PARP protein expression predicts survival in glioblastoma
inhibitors with temozolomide drive PARP1 trapping and patients from an NRG oncology RTOG cohort. Oncology.
apoptosis in Ewing’s sarcoma. PLoS One. 2015;10:e0140988. 2021;99(9):580-588.
doi: 10.1371/journal.pone.0140988 doi: 10.1159/000516168

Volume 3 Issue 1 (2024) 9 https://doi.org/10.36922/td.1480